Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.

Chataway J, Weir CJ, Fox RJ.

Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985. [Epub ahead of print] No abstract available.

PMID:
31218918
2.

Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.

John N, Carroll A, Brownlee WJ, Chataway J.

J Neurol Neurosurg Psychiatry. 2019 May 11. pii: jnnp-2019-320687. doi: 10.1136/jnnp-2019-320687. [Epub ahead of print] No abstract available.

PMID:
31079064
3.

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.

Eshaghi A, Kievit RA, Prados F, Sudre CH, Nicholas J, Cardoso MJ, Chan D, Nicholas R, Ourselin S, Greenwood J, Thompson AJ, Alexander DC, Barkhof F, Chataway J, Ciccarelli O.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):11020-11027. doi: 10.1073/pnas.1818978116. Epub 2019 May 9.

4.

Novel Multiple Sclerosis Drugs in the Pipeline.

De Angelis F, Chataway J.

Clin Pharmacol Ther. 2019 May;105(5):1082-1090. doi: 10.1002/cpt.1412. No abstract available.

PMID:
30986336
5.

Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.

Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, Palladino R, Chataway J, Brescia Morra V.

Mult Scler Relat Disord. 2019 Feb;28:193-196. doi: 10.1016/j.msard.2018.12.042. Epub 2019 Jan 2.

PMID:
30623857
6.

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.

Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K, Meads D, Webb E, Potrata B.

Mult Scler Relat Disord. 2019 Jan;27:370-377. doi: 10.1016/j.msard.2018.11.016. Epub 2018 Nov 17. Review.

PMID:
30476873
7.

Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era.

Lynch DS, Wade C, Paiva ARB, John N, Kinsella JA, Merwick Á, Ahmed RM, Warren JD, Mummery CJ, Schott JM, Fox NC, Houlden H, Adams ME, Davagnanam I, Murphy E, Chataway J.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):543-554. doi: 10.1136/jnnp-2018-319481. Epub 2018 Nov 22. Review.

8.

Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.

Tudor KI, Eames S, Haslam C, Chataway J, Liechti MD, Panicker JN.

J Neurol. 2018 Dec;265(12):2789-2802. doi: 10.1007/s00415-018-9064-8. Epub 2018 Sep 19.

PMID:
30232609
9.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

10.
11.

Innovation as a Driver of Quality and Productivity in UK Healthcare: Creating and Connecting Receptive Places-Emerging Insights.

Marjanovic S, Sim M, Dubow T, Corbett J, Harte E, Parks S, Miani C, Chataway J, Ling T.

Rand Health Q. 2018 Mar 30;7(4):1. eCollection 2018 Mar.

12.

Immune-mediated encephalitis with daclizumab: The final nail.

Williams T, Chataway J.

Mult Scler. 2019 Apr;25(5):753-754. doi: 10.1177/1352458518791374. Epub 2018 Aug 3.

PMID:
30073908
13.

Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

De Angelis F, Plantone D, Chataway J.

CNS Drugs. 2018 Jun;32(6):499-526. doi: 10.1007/s40263-018-0538-0. Review.

PMID:
29968175
14.

2017 McDonald diagnostic criteria: A review of the evidence.

McNicholas N, Hutchinson M, McGuigan C, Chataway J.

Mult Scler Relat Disord. 2018 Aug;24:48-54. doi: 10.1016/j.msard.2018.05.011. Epub 2018 Jun 21. Review.

PMID:
29936325
15.

Validating the portal population of the United Kingdom Multiple Sclerosis Register.

Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV.

Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25.

PMID:
29860199
16.

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists.

J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30.

17.

Tackling progression in multiple sclerosis.

Chataway J.

Lancet Neurol. 2018 Jun;17(6):489-491. doi: 10.1016/S1474-4422(18)30158-3. No abstract available.

PMID:
29778353
18.

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.

Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC; ATX-MS1467 Study Group.

Neurology. 2018 Mar 13;90(11):e955-e962. doi: 10.1212/WNL.0000000000005118. Epub 2018 Feb 21.

PMID:
29467307
19.

Evolving diagnostic criteria for multiple sclerosis.

Chataway J.

Lancet Neurol. 2018 Feb;17(2):118. doi: 10.1016/S1474-4422(17)30463-5. No abstract available.

PMID:
29413308
20.

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O.

Nat Rev Neurol. 2018 Feb;14(2):75-93. doi: 10.1038/nrneurol.2017.171. Epub 2018 Jan 12. Review.

PMID:
29326424
21.

A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.

Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J, Pavitt SH, Schmierer K, Manzano A.

Patient. 2018 Aug;11(4):391-402. doi: 10.1007/s40271-017-0296-y.

22.

Multiple sclerosis, a treatable disease .

Doshi A, Chataway J.

Clin Med (Lond). 2017 Dec;17(6):530-536. doi: 10.7861/clinmedicine.17-6-530. Review.

23.

Grant winners: Track social impact of grant types in Africa.

Chataway J, Hanlin R.

Nature. 2017 Nov 9;551(7679):168. doi: 10.1038/d41586-017-05754-7. No abstract available.

PMID:
29120433
24.

Advancing trial design in progressive multiple sclerosis.

Fox RJ, Chataway J.

Mult Scler. 2017 Oct;23(12):1573-1578. doi: 10.1177/1352458517729768.

25.

Hepatitis C: Understanding Factors That Influence the Physicians' Treatment Decisions.

Miani C, Manville C, Burge P, Marjanovic S, Chataway J.

Rand Health Q. 2017 Jan 1;6(4):6. eCollection 2017 Jan.

26.

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.

Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J.

Lancet Neurol. 2017 Aug;16(8):591-600. doi: 10.1016/S1474-4422(17)30113-8. Epub 2017 Jun 7.

27.

Clinical and genetic characterization of leukoencephalopathies in adults.

Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, Bugiardini E, Freua F, Tavares Lucato L, Macedo-Souza LI, Lakshmanan R, Kinsella JA, Merwick A, Rossor AM, Bajaj N, Herron B, McMonagle P, Morrison PJ, Hughes D, Pittman A, Laurà M, Reilly MM, Warren JD, Mummery CJ, Schott JM, Adams M, Fox NC, Murphy E, Davagnanam I, Kok F, Chataway J, Houlden H.

Brain. 2017 May 1;140(5):1204-1211. doi: 10.1093/brain/awx045.

28.

Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome.

Brownlee WJ, Chataway J.

Mult Scler. 2017 May;23(6):876-877. doi: 10.1177/1352458517693440. Epub 2017 Feb 1. No abstract available.

PMID:
28290753
29.

Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy.

Lakshmanan R, Adams ME, Lynch DS, Kinsella JA, Phadke R, Schott JM, Murphy E, Rohrer JD, Chataway J, Houlden H, Fox NC, Davagnanam I.

Neurol Genet. 2017 Feb 15;3(2):e135. doi: 10.1212/NXG.0000000000000135. eCollection 2017 Apr. Review.

30.

Galvanising the NHS to Adopt Innovation: The Feasibility and Practicality of Recommendations from the Interim Report of the Accelerated Access Review.

Parris S, Cochrane G, Marjanovic S, Ling T, Chataway J.

Rand Health Q. 2016 Jun 20;6(1):8. eCollection 2016 Jun 20.

31.

Evaluating the Role and Contribution of Innovation to Health and Wealth in the UK: A Review of Innovation, Health and Wealth: Phase 1 Final Report.

Bienkowska-Gibbs T, Exley J, Saunders CL, Marjanovic S, Chataway J, MacLure C, McDonald R, Ling T.

Rand Health Q. 2016 Jun 20;6(1):7. eCollection 2016 Jun 20.

32.

The International AIDS Vaccine Initiative's Capacity Building Activities in East Africa: Evaluating Progress and Impacts in Kenya, Uganda and Rwanda.

Cochrane G, Robin E, Hanlin R, Castle-Clarke S, MacLure C, Parks S, Chataway J.

Rand Health Q. 2016 Jan 29;5(3):3. eCollection 2016 Jan 29.

33.

Leadership as a Health Research Policy Intervention: An Evaluation of the NIHR Leadership Programme (Phase 2).

Marjanovic S, Cochrane G, Manville C, Harte E, Chataway J, Jones MM.

Rand Health Q. 2016 Jan 29;5(3):1. eCollection 2016 Jan 29.

34.

Treating clinically isolated syndrome: the long game.

Chataway J.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):284. doi: 10.1136/jnnp-2016-315115. Epub 2017 Jan 9. No abstract available.

PMID:
28069879
35.

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.

Lewin A, Hamilton S, Witkover A, Langford P, Nicholas R, Chataway J, Bangham CRM.

Wellcome Open Res. 2016 Nov 15;1:10. doi: 10.12688/wellcomeopenres.9967.2.

36.

Multiple sclerosis, a treatable disease.

Doshi A, Chataway J.

Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. Review.

37.

Biotin in progressive multiple sclerosis: A new lead?

Chataway J.

Mult Scler. 2016 Nov;22(13):1640-1641. No abstract available.

PMID:
27815562
38.

Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis.

Phé V, Pakzad M, Haslam C, Gonzales G, Curtis C, Porter B, Chataway J, Panicker JN.

Neurourol Urodyn. 2017 Sep;36(7):1770-1775. doi: 10.1002/nau.23173. Epub 2016 Nov 4.

PMID:
27813195
39.

Analysis of Mutations in AARS2 in a Series of CSF1R-Negative Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.

Lynch DS, Zhang WJ, Lakshmanan R, Kinsella JA, Uzun GA, Karbay M, Tüfekçioglu Z, Hanagasi H, Burke G, Foulds N, Hammans SR, Bhattacharjee A, Wilson H, Adams M, Walker M, Nicoll JA, Chataway J, Fox N, Davagnanam I, Phadke R, Houlden H.

JAMA Neurol. 2016 Dec 1;73(12):1433-1439. doi: 10.1001/jamaneurol.2016.2229.

PMID:
27749956
40.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES.

Chataway J.

Mult Scler. 2017 Apr;23(4):505-506. doi: 10.1177/1352458516671821. Epub 2016 Oct 11. Review. No abstract available.

PMID:
27729554
41.

The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.

O'Loughlin E, Hourihan S, Chataway J, Playford ED, Riazi A.

Disabil Rehabil. 2017 Sep;39(18):1821-1828. doi: 10.1080/09638288.2016.1211760. Epub 2016 Aug 16.

PMID:
27685028
42.

New oral drugs for the treatment of multiple sclerosis.

Chard D, Trip A, Chataway J.

Br J Hosp Med (Lond). 2016 Sep 2;77(9):502-3. doi: 10.12968/hmed.2016.77.9.502. No abstract available.

PMID:
27640651
43.

Dimethyl fumarate may still have a role in progressive multiple sclerosis.

Plantone D, De Angelis F, Doshi A, Chataway J.

Ther Adv Neurol Disord. 2016 Jul;9(4):344-5. doi: 10.1177/1756285616640396. Epub 2016 Apr 6. No abstract available.

44.

The N-MOmentum trial: Building momentum to advance trial methodology in a rare disease.

Chataway J, Friede T.

Mult Scler. 2016 Jun;22(7):852-3. doi: 10.1177/1352458516643399. No abstract available.

PMID:
27256900
45.

Clinicopathological case: rapid cognitive decline in an older man.

Scott S, Chataway J, Stone J, Smith C, Davenport R.

Pract Neurol. 2016 Dec;16(6):466-474. doi: 10.1136/practneurol-2015-001322. Epub 2016 Jun 1. No abstract available.

46.

Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Plantone D, De Angelis F, Doshi A, Chataway J.

CNS Drugs. 2016 Jun;30(6):517-26. doi: 10.1007/s40263-016-0340-9. Review.

PMID:
27166830
47.

Bone health in patients with multiple sclerosis relapses.

Murphy O, Zandi MS, Lindenberg N, Murphy E, Chataway J.

Mult Scler Relat Disord. 2016 Mar;6:75-80. doi: 10.1016/j.msard.2016.02.003. Epub 2016 Feb 8.

PMID:
27063628
48.

Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial.

Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Göbel H, Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B.

Eur Heart J. 2016 Jul 7;37(26):2029-36. doi: 10.1093/eurheartj/ehw027. Epub 2016 Feb 22.

PMID:
26908949
49.

Urinary tract infections in multiple sclerosis.

Phé V, Pakzad M, Curtis C, Porter B, Haslam C, Chataway J, Panicker JN.

Mult Scler. 2016 Jun;22(7):855-61. doi: 10.1177/1352458516633903. Epub 2016 Feb 18. Review.

PMID:
26892318
50.

The future of anticoagulation.

Chataway J, Lichten C, Clark E.

Future Cardiol. 2016 Jan;12(1):5-7. doi: 10.2217/fca.15.75. Epub 2015 Dec 21. No abstract available.

Supplemental Content

Loading ...
Support Center